Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Amylyx Pharmaceuticals is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Joshua Cohen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals was founded in 2013 with the mission of improving the lives of patients with neurodegenerative diseases. The company’s lead therapeutic, AMX0035, is designed to simultaneously target pathways originating in the mitochondria and endoplasmic reticulum which lead to neuronal death and degradation. AMX0035 is currently in clinical trials in both Alzheimer’s disease and ALS. The company is focused on evaluating AMX0035 in these indications and, if successful, intends to rapidly provide it to patients in need..

To learn more about Amylyx Pharmaceuticals, visit http://amylyx.com/

Contact:
Joshua Cohen, Chief Executive Officer
617-683-0917
https://www.linkedin.com/in/joshua-cohen-87791a45/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved